guest ::
| Home > Publications Database > Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals. |
| Home > Publications Database > Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals. |
| Journal Article | DZNE-2024-00846 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2024
IOS Press
Amsterdam
This record in other databases: 
Please use a persistent id in citations: doi:10.3233/JAD-231335
Abstract: The NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+:26.6%) and a cluster of participants with overall few symptoms (A+:19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower Aβ42/ptau181 ratio compared to those with neither SCD nor OBJ.The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.
Keyword(s): Humans (MeSH) ; Male (MeSH) ; Female (MeSH) ; Amyloid beta-Peptides: cerebrospinal fluid (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; Aged (MeSH) ; Cognitive Dysfunction: cerebrospinal fluid (MeSH) ; Cognitive Dysfunction: psychology (MeSH) ; Cognitive Dysfunction: diagnosis (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Peptide Fragments: cerebrospinal fluid (MeSH) ; Neuropsychological Tests (MeSH) ; Alzheimer Disease: cerebrospinal fluid (MeSH) ; Alzheimer Disease: psychology (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Middle Aged (MeSH) ; Cohort Studies (MeSH) ; Aged, 80 and over (MeSH) ; Cluster Analysis (MeSH) ; Alzheimer’s disease ; Alzheimer’s disease ; Alzheimer’s disease continuum ; NIA-AA stage 2 ; amyloid ; cerebrospinal fluid biomarkers ; neuropsychiatric symptoms ; preclinical Alzheimer’s disease ; subjective cognitive decline ; Amyloid beta-Peptides ; Biomarkers ; Peptide Fragments ; amyloid beta-protein (1-42) ; Alzheimer’s disease continuum ; preclinical Alzheimer’s disease
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
PDF
PDF (PDFA)